As excitement around ChatGPT and other generative AI programs grows, one company, ZoomRx, has launched its own tool to help transform how pharma analyzes data coming out of medical congresses.
The ChatGPT Revolution Comes To Pharma Business, Starting With Medical Congresses
ZoomRx Has Tweaked ChatGPT For Pharma
ChatGPT’s ability to perform sophisticated analysis and writing tasks has taken the world by storm, and now one developer has launched its own AI aimed at revolutionizing pharma’s business intelligence functions.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.